Bousquets-Muñoz, Pablo http://orcid.org/0000-0002-2969-008X
Díaz-Navarro, Ander http://orcid.org/0000-0001-6808-4800
Nadeu, Ferran http://orcid.org/0000-0003-2910-9440
Sánchez-Pitiot, Ana http://orcid.org/0000-0002-5318-3168
López-Tamargo, Sara http://orcid.org/0000-0002-9468-513X
Shuai, Shimin http://orcid.org/0000-0002-9527-8018
Balbín, Milagros http://orcid.org/0000-0001-5325-0407
Tubio, Jose M. C.
Beà, Sílvia http://orcid.org/0000-0001-7192-2385
Martin-Subero, Jose I. http://orcid.org/0000-0001-8809-5195
Gutiérrez-Fernández, Ana http://orcid.org/0000-0002-9287-8843
Stein, Lincoln D. http://orcid.org/0000-0002-1983-4588
Campo, Elías http://orcid.org/0000-0001-9850-9793
Puente, Xose S. http://orcid.org/0000-0001-9525-1483
Funding for this research was provided by:
Ministerio de Economía y Competitividad (SAF2017-87811-R, SAF2017-87811-R, SAF2017-87811-R)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PMP15/00007, PMP15/00007, PMP15/00007)
"la Caixa" Foundation (HR17-00221, HR17-00221)
"la Caixa" Foundation
Article History
Received: 14 September 2021
Accepted: 15 February 2022
First Online: 14 March 2022
Competing interests
: E.C. has received research funding from Gilead Sciences, and has been consultant for Takeda, Celgene, and Gilead, and is author in a Lymphoma and Leukemia Molecular Profiling Project (LLMPP) patent “Method for selecting and treating lymphoma types” PCT/US14/64161. X.S.P. is co-founder and equity holder of DREAMgenics. The remaining authors declare no competing interests.